左西孟旦在I型心肾综合征的应用

Application of Levosimendan in Type I Cardiorenal Syndrome

摘要: 急性心脏病可伴随缺血性或非缺血性心脏病常出现急性肾损伤，而急性肾损伤是预后不良的独立危险因素，因此在治疗过程中，往往需要关注肾功能的变化。这也使病情更加复杂化，近几年来，左西孟旦作为一种不增加心肌耗氧的钙增敏剂应运而生。根据许多研究，它已被认为在心力衰竭的治疗中，具有一定肾脏保护功能。随着左西孟旦在其他急性心脏病伴心肾综合征中的运用，逐渐发现还有其他的有助于病情改善的作用。本文综述了目前为止关于左西孟旦在I型心肾综合征中的作用和疗效评价的研究报道，旨在能更加全面地认识该药物在I型心肾综合征中的作用并为进一步挖掘其潜能提供思路。

Abstract: Acute heart disease is associated with ischemic or non-ischemic heart disease, and acute kidney injury is an independent risk factor for poor prognosis. Therefore, changes in renal function often need to be paid attention to in the treatment process. This also makes the disease more complicated. In recent years, levosimendan has emerged as a calcium sensitization agent that does not increase the oxygen consumption of the heart muscle. According to many studies, it has been suggested to have some renal protection in the treatment of heart failure. With the use of levosimendan in other acute heart diseases with cardiorenal syndrome, other beneficial effects have been discovered. This paper reviews the current reports on the mechanism of action and efficacy evaluation of levosimendan in type I cardiorenal syndrome, aiming at a more comprehensive understanding of the role of levosimendan in parabolic cardiorenal syndrome and providing ideas for further exploration of its potential.